ESMO 2025: High-Intensity Interval Training Promotes Immune Responses in mNSCLC Patients

At ESMO, Katharina Leuchte, a postdoctoral researcher at the National Center for Cancer Immune Therapy, Herlev-Gentofte Hospital, Denmark, and the University Hospital of Cologne, Germany, presented a randomized controlled trial investigating the combination of exercise and standard-of-care therapy in patients with metastatic non-small cell lung cancer (mNSCLC). In this MEDtalk, she presents the data and discusses the potential clinical benefit for patients in the exercise group.